Clinical trials: Clinical Efficacy
Plaque, Dental, Gingivitis
Efficacy of a Toothpaste in Reducing Plaque, Gingivitis, and Gingival Bleeding
To assess the efficacy of a toothpaste containing chitosan in reducing plaque, gingivitis, and gingival bleeding, compared with Colgate Cavity Protection Toothpaste
- Trial name
- NCT07499115
- Testing
- Toothpaste containing chitosan, Colgate Cavity Protection Toothpaste
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Lipoprotein Disorder
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of HRS-5632 in adult participants with elevated Lipoprotein(a) (Lp(a)) at high risk for cardiovascular events.
- Trial name
- NCT07185776
- Testing
- HRS-5632 Injection
- Where
- 2 sites in China
- Volunteers
- 203 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib in patients hospitalized with moderate-to-severe COVID-19 (based on World Health Organization [WHO]…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05085574
- Testing
- Famotidine, Celecoxib
- Sponsor
- Leidos Life Sciences
Rheumatoid Arthritis
Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis
The purpose of this clinical trial is to determine the optimal dose of HL237 tablets in rheumatoid arthritis patients by comparing the efficacy and safety of the three dose groups of HL237 tablets and the control group.
- Trial name
- NCT04638426
- Testing
- HL237 tablet
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Clostridium Difficile Infection Recurrence
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
This trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy.
- Trial name
- CDI-SCOPE (NCT05831189)
- Testing
- RBX2660
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Ferring Pharmaceuticals
Adults With Neovascular Age-related Macular Degeneration
This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.
Oculgen has begun a study of an investigational drug called OCUL101 as a possible treatment for neovascular AMD. An investigational drug is one that has not been approved by regulatory agencies, such as the Food and Drug…
- Trial name
- STAT (NCT07520318)
- Testing
- bispecific anti-VEGF and anti-complement
- Volunteers
- 255 people
- Sponsor
- Shenzhen Oculgen Biomedical Technology Co., Ltd.
Infertility, Ovulation Induction
A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age
Ovarian reserve is related to chronological age; 35 years of age is the accepted threshold for significant decline in assisted reproductive technologies (ART) success with scarce follicular recruitment and poor oocyte retrieval.
- Trial name
- NCT01079949
- Testing
- r-hLH + r-hFSH, r-hFSH, Recombinant Human Choriogonadotropin (r-hCG)
- Where
- Spain
- Volunteers
- 93 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
This trial is globally conducted. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes…
- Trial name
- PIONEER 7 (NCT02849080)
- Testing
- semaglutide, sitagliptin
- Where
- 83 sites in United States, Argentina and 8 more
- Volunteers
- 504 people
- Sponsor
- Novo Nordisk A/S
Non-small Cell Lung Cancer
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
- Trial name
- NCT04951648
- Testing
- Almonertinib, chemotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with…
- Trial name
- Carolyn-USA (NCT07049055)
- Testing
- E-EDV-D682, EDV-GC, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 144 people
- Sponsor
- Engeneic Pty Limited
Hypertension
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
To compare the safety and efficacy of an aliskiren-based regimen to a lisinopril-based regimen in the treatment of severe hypertension
- Trial name
- NCT00219050
- Testing
- aliskiren
- Where
- 4 sites in Germany, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Novartis
Human Immunodeficiency Virus (HIV)
Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)
The purpose of this study is to compare the antiretroviral activity of doravirine, tenofovir, lamivudine (MK-1439A), a single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing doravirine (MK-1439A) 100 mg +…
- Trial name
- DRIVE-AHEAD (NCT02403674)
- Testing
- Doravirine, Tenofovir, Lamivudine, ATRIPLA™
- Volunteers
- 734 people
- Sponsor
- Merck Sharp & Dohme LLC
Copd, COPD Exacerbation
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.
Preferred pharmacological management for COPD according to the GOLD guidelines are the long-acting anticholinergic LAMAs (Long-Acting / Short-Acting Muscarinic Antagonists), and long-acting β 2-Agonists LABA (Long-acting LABA) /…
- Trial name
- ARGO (NCT05426915)
- Where
- Greece
- Volunteers
- 750 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Type 2 Diabetes Mellitus
A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus
The study is aimed at evaluating efficacy and safety of GRC 8200 in type 2 diabetes mellitus patients. The study involves six weeks of wash out period and two weeks run in period for patients currently on mono-therapy and a two…
- Trial name
- NCT00836940
- Testing
- GRC 8200
- Where
- India
- Volunteers
- 480 people
- Sponsor
- Glenmark Pharmaceuticals Europe Ltd. (R&D)
Dermatitis, Atopic
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy of 611 in Chinese Adolescents with moderate to severe atopic dermatitis.
- Trial name
- NCT07042126
- Testing
- 611
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Cataract
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
- Trial name
- NCT06333015
- Testing
- enVista Beyond EY (EDF) IOL, enVista MX60E monofocal IOL
- Where
- 16 sites in United States
- Volunteers
- 304 people
- Sponsor
- Bausch & Lomb Incorporated
Advanced Solid Tumors
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors
- Trial name
- NCT05951608
- Testing
- AK127 in combination with AK112
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Akeso
Multiple Myeloma
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
To evaluate the safety and efficacy of Human BCMA Targeted T Cells Injection for the treatment of BCMA-positive relapsed/refractory multiple myeloma.
- Trial name
- NCT04003168
- Testing
- Human BCMA targeted T Cells Injection
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Corneal Disease, Corneal Opacity
First in Human (FIH) Study to Assess Safety and Efficacy of the CorNeat KPro for the Treatment of Corneal Blindness
Prospective, open label, single arm, First in Human (FIH) clinical study to assess safety and efficacy of the CorNeat Keratoprosthesis, a synthetic cornea, for the treatment of corneal blindness
- Conditions
- Corneal Disease, Corneal Opacity, Corneal Injuries
- Trial name
- NCT04485858
- Testing
- CorNeat KPro
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 10 people
- Sponsor
- CorNeat Vision Ltd.
Focus of Study is STEMI
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
This study explores the potential cardioprotective properties of danegaptide when administered to patients with ST-Segment elevation myocardial infarction.
- Trial name
- NCT01977755
- Testing
- danegaptide
- Where
- Denmark
- Volunteers
- 591 people
- Sponsor
- Zealand Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.